AFFIRM-AHF: Ferric Carboxymaltose in Iron-Deficient Patients Discharged After Acute Heart Failure

November 13-17, 2020; Virtual Conference
In patients with iron deficiency, FCM reduced risk of HFH with no apparent effect on risk of CV death.
Format: Microsoft PowerPoint (.ppt)
File Size: 244 KB
Released: November 18, 2020


Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from

Related Content

Expert video from Clinical Care Options (CCO) on optimal prevention and management of CV morbidities in settings of heart failure, diabetes, and CKD

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC Javed Butler, MD, MPH, MBA Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: December 15, 2020 Expired: December 14, 2021

CCO slides from Deepak Bhatt, Javed Butler: Latest on SGLT2 inhibitors in HF, emerging therapies in HFrEF, timing of ARNI initiation in decompensated HF, and more.

Released: December 9, 2020

Expert commentary on key highlights in heart failure from AHA 2020, provided by Clinical Care Options

Javed Butler, MD, MPH, MBA Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: December 9, 2020 Expired: December 8, 2021

High-dose trivalent influenza vaccine comparable to standard-dose quadrivalent vaccine in deaths or cardiopulmonary hospitalizations in high-risk CV disease; AHA results reported by CCO

Released: November 20, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.